GSK/$GSK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GSK
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Ticker
$GSK
Sector
Health
Primary listing
NYSE
Employees
68,629
Headquarters
Website
GSK Metrics
BasicAdvanced
$75B
33.84
$1.11
0.27
$1.58
4.48%
Price and volume
Market cap
$75B
Beta
0.27
52-week high
$44.67
52-week low
$31.72
Average daily volume
5.6M
Dividend rate
$1.58
Financial strength
Current ratio
0.867
Quick ratio
0.555
Long term debt to equity
106.618
Total debt to equity
120.9
Dividend payout ratio (TTM)
72.80%
Interest coverage (TTM)
10.25%
Profitability
EBITDA (TTM)
12,485.896
Gross margin (TTM)
71.69%
Net profit margin (TTM)
10.82%
Operating margin (TTM)
20.13%
Effective tax rate (TTM)
13.80%
Revenue per employee (TTM)
$618,180
Management effectiveness
Return on assets (TTM)
6.78%
Return on equity (TTM)
28.33%
Valuation
Price to earnings (TTM)
33.845
Price to revenue (TTM)
3.605
Price to book
3.78
Price to tangible book (TTM)
-7.65
Price to free cash flow (TTM)
23.537
Free cash flow yield (TTM)
4.25%
Free cash flow per share (TTM)
1.597
Dividend yield (TTM)
4.21%
Forward dividend yield
4.48%
Growth
Revenue change (TTM)
0.59%
Earnings per share change (TTM)
-15.48%
3-year revenue growth (CAGR)
4.37%
10-year revenue growth (CAGR)
3.09%
3-year earnings per share growth (CAGR)
-9.68%
10-year earnings per share growth (CAGR)
-10.43%
3-year dividend per share growth (CAGR)
-9.94%
10-year dividend per share growth (CAGR)
-4.52%
What the Analysts think about GSK
Analyst ratings (Buy, Hold, Sell) for GSK stock.
GSK Financial Performance
Revenues and expenses
GSK Earnings Performance
Company profitability
GSK News
AllArticlesVideos
GSK to Receive $370 Million in U.S. Patent Litigation Settlement
WSJ·7 hours ago
GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute
Proactive Investors·7 hours ago
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
WSJ·7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Aug15
GSK
Dividend·Ex-dividend
Oct9
GSK
Dividend·Payment
$0.428118Per share
FAQs
What’s the current market cap for GSK stock?
GSK (GSK) has a market cap of $75B as of August 08, 2025.
What is the P/E ratio for GSK stock?
The price to earnings (P/E) ratio for GSK (GSK) stock is 33.84 as of August 08, 2025.
Does GSK stock pay dividends?
Yes, the GSK (GSK) stock pays dividends to shareholders. As of August 08, 2025, the dividend rate is $1.58204 and the yield is 4.48%. GSK has a payout ratio of 72.8% on a trailing twelve-month basis.
When is the next GSK dividend payment date?
The next GSK (GSK) dividend payment is scheduled for October 09, 2025.
What is the beta indicator for GSK?
GSK (GSK) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.